易瑞生物
(300942)
| 流通市值：39.25亿 | | | 总市值：39.25亿 |
| 流通股本：4.01亿 | | | 总股本：4.01亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 49,342,908.97 | 224,249,109.55 | 158,047,893.25 | 103,648,296.2 |
| 营业收入 | 49,342,908.97 | 224,249,109.55 | 158,047,893.25 | 103,648,296.2 |
| 二、营业总成本 | 55,561,251.36 | 210,280,739.07 | 158,868,141.37 | 102,619,327.37 |
| 营业成本 | 23,502,052.28 | 65,866,774.58 | 53,588,701.95 | 32,507,523.28 |
| 税金及附加 | 373,258.43 | 876,429.6 | 520,489.87 | 282,150.81 |
| 销售费用 | 11,594,548.43 | 44,967,534.44 | 33,407,800.88 | 23,216,436.38 |
| 管理费用 | 10,410,223.57 | 50,257,681.99 | 36,254,699.8 | 24,772,539.16 |
| 研发费用 | 8,238,945.94 | 40,452,354.02 | 28,803,950.34 | 20,120,962.89 |
| 财务费用 | 1,442,222.71 | 7,859,964.44 | 6,292,498.53 | 1,719,714.85 |
| 其中:利息费用 | 6,417,543.56 | 18,666,370.68 | 12,079,658.33 | 8,276,316.34 |
| 其中:利息收入 | 3,900,514.06 | 8,328,421.46 | 6,800,390.26 | 5,596,269.9 |
| 加:公允价值变动收益 | 903,784.58 | 1,871,304.38 | 2,233,169.07 | 355,062.33 |
| 加:投资收益 | -2,089,627.24 | -5,849,539.02 | -6,044,038.73 | -3,040,256.3 |
| 资产处置收益 | 135,280.15 | 2,283,492.87 | 2,672,938.87 | 1,087,574.66 |
| 资产减值损失(新) | - | -2,143,668.7 | -183,835.18 | - |
| 信用减值损失(新) | 1,366,844.92 | -8,040,953.76 | -5,485,906.79 | -3,769,976.3 |
| 其他收益 | 873,863.02 | 18,875,970.9 | 12,695,410.62 | 3,194,605.35 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -5,028,196.96 | 20,964,977.15 | 5,067,489.74 | -1,144,021.43 |
| 加:营业外收入 | 8,991.15 | 356,648.58 | 150,688.87 | 14,579.53 |
| 减:营业外支出 | 15,440.06 | 1,632,563.17 | 498,992.43 | 108,479.9 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -5,034,645.87 | 19,689,062.56 | 4,719,186.18 | -1,237,921.8 |
| 减:所得税费用 | -800,897.98 | 3,069,654.27 | 1,731,957.86 | 714,904.32 |
| 六、净利润 | -4,233,747.89 | 16,619,408.29 | 2,987,228.32 | -1,952,826.12 |
| 持续经营净利润 | -4,233,747.89 | 16,619,408.29 | 2,987,228.32 | -1,952,826.12 |
| 归属于母公司股东的净利润 | -3,346,003.68 | 17,116,524.08 | 3,896,966.64 | -1,559,498.42 |
| 少数股东损益 | -887,744.21 | -497,115.79 | -909,738.32 | -393,327.7 |
| (一)基本每股收益 | -0.01 | 0.04 | 0.01 | 0 |
| (二)稀释每股收益 | -0.01 | 0.04 | 0.01 | 0 |
| 八、其他综合收益 | -209,889.51 | -171,733.24 | -64,861.63 | -1,474.29 |
| 归属于母公司股东的其他综合收益 | -209,889.51 | -171,733.24 | -64,861.63 | -1,474.29 |
| 九、综合收益总额 | -4,443,637.4 | 16,447,675.05 | 2,922,366.69 | -1,954,300.41 |
| 归属于母公司股东的综合收益总额 | -3,555,893.19 | 16,944,790.84 | 3,832,105.01 | -1,560,972.71 |
| 归属于少数股东的综合收益总额 | -887,744.21 | -497,115.79 | -909,738.32 | -393,327.7 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-29 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |